Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Research Letters
Open Access

Preliminary Assessment of Acute Kidney Injury in Critically Ill Children Associated with SARS-CoV-2 Infection

A Multicenter Cross-Sectional Analysis

Erica C. Bjornstad, Kelli A. Krallman, David Askenazi, Michael Zappitelli, Stuart L. Goldstein, Rajit K. Basu and on behalf of the SPARC Investigators
CJASN November 2020, CJN.11470720; DOI: https://doi.org/10.2215/CJN.11470720
Erica C. Bjornstad
1Division of Nephrology, Department of Pediatrics, Children’s of Alabama, University of Alabama Birmingham, Birmingham, Alabama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kelli A. Krallman
2Division of Nephrology and Hypertension, Center for Acute Care Nephrology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Askenazi
1Division of Nephrology, Department of Pediatrics, Children’s of Alabama, University of Alabama Birmingham, Birmingham, Alabama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Zappitelli
3Division of Nephrology, Hospital for Sick Children, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stuart L. Goldstein
2Division of Nephrology and Hypertension, Center for Acute Care Nephrology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rajit K. Basu
4Division of Critical Care, Department of Pediatrics, Children’s Healthcare of Atlanta, Emory University, Atlanta, Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading
  • COVID-19
  • critically ill children
  • acute kidney injury

The virus, severe acute respiratory syndrome coronavirus 2, that causes coronavirus disease 2019 (COVID-19) infected >12 million people around the world as of July 2020 (Johns Hopkins Coronavirus Tracker). Knowledge on pathophysiology, management, multiorgan effects, and postinfection complications is evolving. Several studies revealed variable AKI prevalence among hospitalized adults with COVID-19, as high as 76% in critically ill adults with higher risk of mortality (1). To our knowledge, no specific epidemiologic data on AKI in critically ill children with COVID-19 have been published, leading to gaps in our ability to plan for its implications in this ongoing pandemic.

We are conducting a multicenter, point-prevalence AKI study among critically ill children with COVID-19. We provide an epidemiologic snapshot of AKI among this cohort.

This cross-sectional analysis captured weekly data points. This interim analysis includes children (1 month to 18 years) from 41 centers (six countries; 32 in the United States) with confirmed severe acute respiratory syndrome coronavirus 2–positive diagnosis (on the basis of center testing protocols) admitted to intensive care units (ICUs) between April 15 and May 20, 2020.

The primary outcome was AKI defined by Kidney Disease Improving Global Outcomes creatinine criteria. Admission and peak creatinine on data capture days (or previous day if unavailable) were used. Baseline creatinine was the lowest within 3 months before admission or, if unknown, estimated using previously validated methods (2). Hospital outcomes censored at 14 days were (1) deceased, (2) hospitalized in ICU ≥14 days, or (3) presumed ICU hospitalization <14 days (when a patient is not included in two weekly date capture time points or not included in three date capture points and length of stay dates are <14 days). Final 28-day hospital mortality was determined.

Characteristics of participants with AKI versus participants without AKI were compared using distribution-appropriate univariable analyses. For characteristics with P value ≤0.10, univariable relative risks (RRs; 95% confidence intervals [95% CIs]) of AKI were calculated.

All centers’ ethical review boards approved the study and waived consent requirement. Deidentified data were electronically entered into REDCap, and analysis was conducted in SAS, version 9.4.

Only 26 of 41 (63%) centers (23 in the United States, three in Europe/Russia) had critically ill children who were COVID-19 positive during our catchment days. Of 106 included children, almost half (n=47; 44%; 95% CI, 35% to 54%) developed AKI: 47% (n=22) had stage 1, 23% (n=11) had stage 2, and 30% (n=14) had stage 3. No child received dialysis. Even though 71 children lacked baseline creatinine, AKI estimates were similar between those with and without a baseline creatinine (46%; 95% CI, 29% to 62% and 44%; 95% CI, 32% to 55%, respectively).

Table 1 displays demographic and clinical characteristics of children with and without AKI. Most children had at least one comorbidity (n=71; 67%), and almost 6% died (n=6). Vasopressor support and admission diagnosis of shock/hemodynamic instability were the only factors associated with higher risk for AKI (RR, 1.6; 95% CI, 1.1 to 2.5 and RR, 2.3; 95% CI, 1.5 to 3.5, respectively).

View this table:
  • View inline
  • View popup
Table 1.

Epidemiology of AKI development among critically ill children who are coronavirus disease 2019 positive

We found a high prevalence of AKI among critically ill children with COVID-19 (44%). This matches what has been seen in adult ICU AKI studies on COVID-19 (1). Compared with previous pediatric ICU-associated AKI research, the AKI prevalence with COVID-19 was much higher (44% versus 26%), although differences exist in inclusion criteria and centers (3).

We did not see the degree of AKI severity as seen in adult COVID-19 studies as no child in this analysis received dialysis. It should be noted that our cohort comes primarily from the United States during the earlier part of the COVID-19 pandemic, when testing was limited and children were more isolated. Subsequent waves of the pandemic may appear differently. Despite general findings of less severe disease in children compared with adults, 6% of our study population died. This raises concerns given the rising cases of COVID-19 globally and in the United States specifically, and a recent prediction model suggests that if COVID-19 remains unabated, pediatric ICUs could be overwhelmed (4). Our findings should be confirmed with additional in-depth pediatric studies.

Only half of participating centers had patients with COVID-19 to include during the analysis period. It could be argued that children are less likely to contract COVID-19, but newer reports suggest otherwise, with rising pediatric cases. Our 6% mortality rate suggests that pediatric severe disease is certainly possible. Thus, we feel low inclusion rates at some centers may primarily be driven by minimized transmission to children as a downstream effect of good population-level control.

It is important to note that our AKI estimate is likely an underestimation as we only used creatinine change to define AKI and not urine output.

We observed a high prevalence of AKI in critically ill children with COVID-19. With the rising cases worldwide, particularly in the United States, it is likely that AKI rates in critically ill children will also rise. With the complexity that AKI adds to the medical care of children, clinicians need to be even more diligent with early AKI identification, careful attention to fluid balance, and minimization of nephrotoxic medications, so that these patients do not suffer potentially avoidable consequences.

Disclosures

D. Askenazi reports consultancy agreements with AKI Foundation, Baxter, Bioporto, Inc., CHF Solutions, and Medtronic and receiving research funding from Baxter Renal Products and CHF Solutions. R.K. Basu reports consultancy agreements with Baxter Healthcare Solutions, BD, Biomerieux, BioPorto Diagnostics, and Potrero and speakers bureau for Baxter and BioPorto Diagnostics. E.C. Bjornstad reports that Bioporto, Inc. provided free supplies for a past research project in Malawi (using their NGALds dipstick). S.L. Goldstein reports consultancy agreements with Baxter Healthcare, Bioporto, Inc., CHF Solutions, Fresenius, Kaneka, Inc., La Jolla Pharmaceuticals, MediBeacon, Medtronic, Otsuka, Reata, and Renibus; ownership interest in MediBeacon; receiving research funding from Baxter Healthcare, Bioporto, Inc., and CHF Solutions; receiving honoraria from Baxter Healthcare and Fresenius; patents and inventions with Vigilanz; serving as a scientific advisor or member of MediBeacon; and speakers bureau for Baxter Healthcare and Fresenius. M. Zappitelli reports consultancy agreements with Bioporto, Inc., CytoPheryx Inc., and Eloxx Pharmaceuticals; receiving honoraria from Bioporto, Inc. and Eloxx Pharmaceuticals; and other interests/relationships with the Canadian Pediatric Nephrologists Association, the Canadian Society of Nephrology, and the Kidney Foundation of Canada. The remaining author has nothing to disclose.

Funding

Grant support was provided by National Institutes of Health grant 2UL1TR001425-05A1.

Acknowledgments

Our centralized data collection is housed at Cincinnati Children’s Hospital Medical Center via grant support from the Center for Clinical and Translational Science and Training (2UL1TR001425-05A1).

Footnotes

  • ↵* The SPARC Investigators are Katherine Irby, Paras Khandhar, Catherine Morgan, Erica Blender Brown, Sarah Velazquez de Leon, Ronke Awojoodu, Barsha Chakraborty, Mark Peters, Vamsi Yarlagadda, Cody Tigges, Rukshana Shroff, Allie Michelle DaCar, Felice Su, Ayse Arikan, Joana Tala, David Kwiatkowski, Emily Duffey, Rosario Ocampo, Rebecca Hammack, Utpal Bhalala, Werther Brunow de Carvalho, Glenda Hefley, Cathy Sheppard, Ronish Gupta, Vimal Chadha, Diane Liu, Beatrice Goilav, Minh Dien Duong, Alexandra Mazo, Nayan Shetty, Laura O’Malley, Dawn Jones, Christine Batchelder, Matthew Barhight, Elizabeth Kring, Amanda Hassinger, Catherine Ross, Nadine Straka, Pooja Nawathe, Gary Goulin, Stephen Gorga, Chaandini Jayachandran, Itay Ayalon, Sameer Kamath, Melissa Harward, Susan Martin, Natasa Stajic, Katja Gist, Jennifer Jetton, Brynna Van Wyk, Dwight Bailey, Jennifer Lamothe, Lee Polikoff, Navya Kirla, Rahul Chanchlani, David Selewski, Dana Fuhrman, Cassandra Formeck, Noureddin Nourbakhsh, Michelle Starr, Shina Menon, Hirotsugu Kitayama, Chris Parshuram, Jasmine Lee, Scott Sutherland, Felice Su, Robert Woroniecki, Rachel Sirignano, Leanna Huard, Brankica Spasojevic, Snezana Rsovac, Joshua Frazier, William Bortcosh, Duane Williams, E. Vincent S. Faustino, Casey Stulce, Aveneh Ghanam, Grace Chong, Vikas Dharnidharka, Tara Neumayr, Daniel Garros, Lydia Fong, Gonzalo Guerra, Akash Deep, Richard Hackbarth, Sapna Kudchadkar, Julie Fitzgerald, Rosario O’Campo, Anuj Khatri, Leslie Walther, Irene Pacheco, Pranali Awadhare, Ivana Cerovic, Bijana Medjo, Zaccaria Ricci, Rashid Alobaidi, Sean Bagshaw, Brendan Crawford, Richard Blaszak, Juan Francisco Collado Caparros, Yael Feinstein, and Michelle Moss.

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • Copyright © 2021 by the American Society of Nephrology

References

  1. ↵
    1. Hirsch JS,
    2. Ng JH,
    3. Ross DW,
    4. Sharma P,
    5. Shah HH,
    6. Barnett RL,
    7. Hazzan AD,
    8. Fishbane S,
    9. Jhaveri KD; Northwell COVID-19 Research Consortium and the Nephrology COVID-19 Research Consortium
    : Acute kidney injury in patients hospitalized with COVID-19. Kidney Int 98: 209–218, 2020 pmid:32416116
    OpenUrlCrossRefPubMed
  2. ↵
    1. Hessey E,
    2. Ali R,
    3. Dorais M,
    4. Morissette G,
    5. Pizzi M,
    6. Rink N,
    7. Jouvet P,
    8. Lacroix J,
    9. Phan V,
    10. Zappitelli M
    : Evaluation of height-dependent and height-independent methods of estimating baseline serum creatinine in critically ill children. Pediatr Nephrol 32: 1953–1962, 2017 pmid:28523356
    OpenUrlCrossRefPubMed
  3. ↵
    1. Kaddourah A,
    2. Basu RK,
    3. Bagshaw SM,
    4. Goldstein SL
    ; AWARE Investigators: Epidemiology of acute kidney injury in critically ill children and young adults. N Engl J Med 376: 11–20, 2017 pmid:27959707
    OpenUrlCrossRefPubMed
  4. ↵
    1. Pathak EB,
    2. Salemi JL,
    3. Sobers N,
    4. Menard J,
    5. Hambleton IR
    : COVID-19 in children in the United States: Intensive care admissions, estimated total infected, and projected numbers of severe pediatric cases in 2020. J Public Health Manag Pract 26: 325–333, 2020 pmid:32282440
    OpenUrlCrossRefPubMed
    1. Goldstein SL,
    2. Dahale D,
    3. Kirkendall ES,
    4. Mottes T,
    5. Kaplan H,
    6. Muething S,
    7. Askenazi DJ,
    8. Henderson T,
    9. Dill L,
    10. Somers MJG,
    11. Kerr J,
    12. Gilarde J,
    13. Zaritsky J,
    14. Bica V,
    15. Brophy PD,
    16. Misurac J,
    17. Hackbarth R,
    18. Steinke J,
    19. Mooney J,
    20. Ogrin S,
    21. Chadha V,
    22. Warady B,
    23. Ogden R,
    24. Hoebing W,
    25. Symons J,
    26. Yonekawa K,
    27. Menon S,
    28. Abrams L,
    29. Sutherland S,
    30. Weng P,
    31. Zhang F,
    32. Walsh K
    : A prospective multi-center quality improvement initiative (NINJA) indicates a reduction in nephrotoxic acute kidney injury in hospitalized children. Kidney Int 97: 580–588, 2020 pmid:31980139
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 16 (2)
Clinical Journal of the American Society of Nephrology
Vol. 16, Issue 2
February 08, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Preliminary Assessment of Acute Kidney Injury in Critically Ill Children Associated with SARS-CoV-2 Infection
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Preliminary Assessment of Acute Kidney Injury in Critically Ill Children Associated with SARS-CoV-2 Infection
Erica C. Bjornstad, Kelli A. Krallman, David Askenazi, Michael Zappitelli, Stuart L. Goldstein, Rajit K. Basu, on behalf of the SPARC Investigators
CJASN Nov 2020, CJN.11470720; DOI: 10.2215/CJN.11470720

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Preliminary Assessment of Acute Kidney Injury in Critically Ill Children Associated with SARS-CoV-2 Infection
Erica C. Bjornstad, Kelli A. Krallman, David Askenazi, Michael Zappitelli, Stuart L. Goldstein, Rajit K. Basu, on behalf of the SPARC Investigators
CJASN Nov 2020, CJN.11470720; DOI: 10.2215/CJN.11470720
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Funding
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Prolonged SARS-CoV-2 Viral RNA Shedding and IgG Antibody Response to SARS-CoV-2 in Patients on Hemodialysis
  • Effect of Sickle Cell Trait and APOL1 Genotype on the Association of Soluble uPAR with Kidney Function Measures in Black Americans
  • Characteristics of Acute Kidney Injury in Hospitalized COVID-19 Patients in an Urban Academic Medical Center
Show more Research Letters

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Keywords

  • COVID-19
  • critically ill children
  • acute kidney injury

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire